Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8% LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8%
Earnings

Pharmacorp Rx Inc. Reports Q3 2025 Financial Results

By The Northwire Desk — AI Analysis Nov 28, 2025 · 19:44 PCRX · 0.41 PharmaCorp Rx Inc.
PCRX · Price

Executive Summary

  • PharmaCorp Rx Inc. reported Q3 2025 financial results, showing strong same‑store sales growth (+9.4% YoY) and prescription volume increase (+7.2% YoY).
  • The company completed acquisitions of three pharmacies (two in Western Canada, one in Eastern Canada) for a total purchase price of C$8.7 million, funded with cash, shares, and its credit facility.
  • PharmaCorp closed a bought‑deal public offering of 54,855,000 units at C$0.42 per unit, raising approximately C$23.0 million in gross proceeds.

Key Details

  • Financial Highlights (Q3 2025):
  • Same‑store sales up 9.4% YoY.
  • Total script count up 7.2% YoY.

  • Net loss for the quarter attributed to corporate infrastructure investments, director/officer stock options, and one‑time legal fees for a CIBC credit facility.

  • Acquisitions (completed post‑quarter):

  • Two Western Canada pharmacies purchased for an aggregate price of C$3.4 million (cash + shares).

  • One Eastern Canada pharmacy purchased for C$5.3 million (cash + available credit facility funds).

  • Public Offering (bought deal):

  • Units sold: 54,855,000 (including full over‑allotment option).
  • Price per unit: C$0.42.

  • Gross proceeds to PharmaCorp: ≈ C$23.0 million.

  • Use of Proceeds (implied): Funding acquisitions, corporate infrastructure, and working capital; specific allocation not detailed in release.

  • Management Commentary: Executive Chairman Alan Simpson highlighted “steady progress in scaling the business through disciplined, methodical execution” and reaffirmed commitment to maintaining a weighted‑average EBITDA multiple across transactions for accretive growth.

  • Operational Update: Investments made in systems, personnel, and integration processes to support national scalability; net loss includes stock options granted on July 18 2025 and legal fees for credit facility.

Notable Quotes

“We’re encouraged by the strong performance of our initial acquisitions and by the ongoing interest from independent pharmacy owners considering their succession options,” – Alan Simpson, Executive Chairman, PharmaCorp Rx Inc.

All forward‑looking statements are subject to risks and uncertainties detailed in the release.

Read the original news release →

More from PharmaCorp Rx Inc.

Jun 29, 2026 · 07:16

PharmaCorp Announces Definitive Agreement to Acquire Western Canada PharmaChoice Bannered Pharmacy

M&A / Property Jun 01, 2026 · 09:00

PharmaCorp Rx Inc. Consolidates Eastern Canada Footprint as Q1 Revenue Surges 79%, Yet Margin Compression and Integration Pace Demand Caution

Earnings May 25, 2026 · 09:27

PharmaCorp Rx Advances National Footprint with Definitive Acquisition, Pipeline Execution Validates Growth Strategy

M&A / Property May 01, 2026 · 17:00

PharmaCorp Rx Inc.

M&A / Property Apr 30, 2026 · 11:04

PharmaCorp Doubles Footprint, Cash Reserves Depleted by Aggressive Buyout

M&A / Property Apr 29, 2026 · 20:51

PharmaCorp Rx Confirms M&A Execution but Stock Stalls Near Dilutive Offering Price

Earnings